Ocular Therapeutix, Inc. Share Price & Technical Analysis
OCUL · $8.23 (+0.12%)
Healthcare / Biotechnology
$8.23
+0.12%
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-13% return in May, 5% avg return in past 3 year May month.
-34% return in 2026, 86% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -25% | -2% | -2% | 8% | -13% | – | – | – | – | – | – | – | -34% |
| 25 | -10% | -7% | 6% | 14% | -4% | 16% | 26% | 7% | -2% | -3% | 4% | 0% | 47% |
| 24 | 11% | 106% | -10% | -48% | 16% | 17% | 25% | 2% | 1% | 22% | -6% | -13% | 124% |
| 23 | 34% | 54% | -12% | 17% | 3% | -19% | -12% | -16% | -18% | -10% | -17% | 80% | 86% |
| 22 | -19% | -2% | -4% | -27% | -14% | 25% | 10% | 16% | -18% | -14% | -19% | -7% | -72% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.98B
P/E ratio
—
52W high
$16.44
52W low
$6.23
Volume
20,32,363
Beta
0.93
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Ocular Therapeutix, Inc. share price today?
- Ocular Therapeutix, Inc. (OCUL) last traded around $8.23 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does OCUL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for OCUL. Download the app for real-time alerts.
- How can I analyze Ocular Therapeutix, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.